Compare KRRO & WALD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRRO | WALD |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | United Kingdom |
| Employees | N/A | 364 |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.0M | 179.6M |
| IPO Year | 2019 | N/A |
| Metric | KRRO | WALD |
|---|---|---|
| Price | $11.21 | $1.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $34.80 | $2.00 |
| AVG Volume (30 Days) | 122.0K | ★ 624.0K |
| Earning Date | 05-13-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,392,000.00 | N/A |
| Revenue This Year | N/A | $9.89 |
| Revenue Next Year | N/A | $4.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 181.46 | N/A |
| 52 Week Low | $5.20 | $0.72 |
| 52 Week High | $55.89 | $3.22 |
| Indicator | KRRO | WALD |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 58.90 |
| Support Level | $10.81 | $1.50 |
| Resistance Level | $14.42 | $2.00 |
| Average True Range (ATR) | 0.99 | 0.18 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 42.92 | 62.03 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.